The 24-Hour Thrombolysis Window — A New Standard for Acute Ischemic Stroke

The Clinical Scenario

Picture this: it's 10 PM, and the stroke pager goes off. A 67-year-old woman arrives to the ED with right-sided weakness and aphasia. Her symptoms started around noon but she couldn't find help, by time she arrived to ED, it has been ten hours already — maybe more.

Twelve years ago, she would have been turned away from thrombolysis before the conversation even started. Five years ago, she might have qualified for an endovascular study if she had a large vessel occlusion. In 2026, she's a candidate for IV tenecteplase — not because we bent the rules, but because the rules finally caught up with the biology.

This is the quiet revolution in acute stroke care. The clock on the wall no longer decides who gets treated. The brain does.

How We Got Here: A Brief History of the IVT Window

The story of thrombolysis in stroke is really a story about caution — fear of bleeding, fear of futility, and fear of treating the wrong patient at the wrong time. That caution has shaped every guideline, every protocol, every middle-of-the-night conversation with a family in the CT suite.

In 1995, the NINDS rt-PA trial gave us the original three-hour window. The selection criteria were brutally simple: a noncontrast head CT to rule out hemorrhage, a last-known-well time under three hours, and not much else. The trial was positive, but narrow — and the window felt arbitrary even then. It was based on enrollment feasibility, not on any deep understanding of penumbral survival.

ECASS III in 2008 extended the window to 4.5 hours, but only for a carefully selected subset: patients under 80, without diabetes plus prior stroke, with NIHSS ≤25. The message was clear: we'll go a little further, but only if you're lower risk. The 4.5-hour ceiling became gospel — taught in residency, baked into protocols, defended in quality metrics.

Then came the imaging era. WAKE-UP in 2018 didn't actually extend the window in a traditional sense — it redefined it. By using DWI-FLAIR mismatch to identify patients whose tissue age was still within a favorable range, the trial showed that the wall clock was the wrong reference point. What mattered wasn't the last known well. It was whether there was still brain worth saving.

That conceptual shift — from time-based to tissue-based selection — opened the floodgates. If you could identify penumbra on imaging, why stop at 4.5 hours? Why stop at wake-up strokes?

EXTEND, published in 2019, tested that hypothesis directly. Using CT perfusion to select patients with mismatch (core <70 mL, mismatch ratio ≥1.2), the trial enrolled patients out to nine hours. The results were positive: mRS 0–1 in 35.4% vs 29.5%, despite a higher rate of symptomatic ICH (6.2% vs 0.9%). The benefit was real. The bleeding was manageable. The window had moved.

And then, starting in 2024, came the wave: TIMELESS, TRACE-III, CHABLIS-T II, EXPECTS, OPTION — trials pushing the boundary all the way to 24 hours. The question was no longer can we treat beyond 4.5 hours. It was how do we do it safely, and for whom.

The Old Fear: "Late Brain Bleeds"

The 4.5-hour ceiling wasn't arbitrary. It rested on a biological hypothesis that made intuitive sense: ischemic tissue, after a certain point, becomes fragile. The blood-brain barrier breaks down. Give tPA into that environment, and you're risking for hemorrhage — symptomatic, disabling, sometimes fatal.

The early extended-window trials seemed to confirm that fear. EXTEND's 6.2% sICH rate was more than six times higher than the control arm. That number made people nervous. But here's what the data also showed: the benefit outweighed the risk. Even with more bleeding, more patients walked out of the hospital independent.

The question wasn't whether late thrombolysis caused more hemorrhage. It was whether we could refine selection enough to shrink that risk while preserving the benefit. And as it turns out — we could.

How sICH Dropped from 6% to <3%

The key was mismatch. Not just any mismatch — the right mismatch. Early trials like EXTEND cast a wide net: core <70 mL, ratio ≥1.2. That's permissive. As subsequent trials tightened the criteria — requiring smaller cores (<50 mL in some), higher mismatch ratios, better exclusion of patients with early infarct signs — the hemorrhage rates came down.

TRACE-III reported sICH at 3.0%. TIMELESS at 3.2%. OPTION, in a purely non-LVO cohort, saw 2.8%. These are not materially different from the 0–4.5 hour window in routine practice. We didn't eliminate the risk. We selected it away.

Other factors helped:

• Avoidance of large-core LVO. If the core is already >70 mL, lysis won't help — and it might harm. Modern trials exclude these patients upfront.
• Tenecteplase over alteplase. TNK's superior fibrin specificity may reduce off-target bleeding. It's also a single bolus, which makes workflow cleaner and dosing errors less likely.
• Better imaging interpretation. Radiologists and vascular neurologists have gotten much better at reading CTP — distinguishing true penumbra from benign oligemia, recognizing artifact, and integrating clinical context.

The result: late thrombolysis, done right, is about as safe as early thrombolysis done poorly. The difference is in the selection.

The Evidence Base: Trial by Trial

Let's walk through the data. Not as a list of abstracts, but as a body of evidence that tells a coherent story.

What the Data Tells Us

WAKE-UP proved the concept: tissue-based selection works, even when you don't know the time. The 11.5-percentage-point absolute benefit in functional independence was striking — and it came with minimal bleeding risk.

EXTEND was the bridge trial. It took the WAKE-UP principle and pushed it into a defined late window. Yes, sICH was higher. But the net benefit was undeniable, and it set the stage for everything that followed.

TIMELESS was the disappointing neutral result — but it taught us something important. In patients in the late window with LVO, already going for thrombectomy, the marginal benefit of adding thrombolysis gets smaller. TIMELESS wasn't a failure of the drug. It was a success of the system.

TRACE-III, by contrast, was robustly positive in a population where thrombectomy access was not available and imaging selection was meticulous. The 9-percentage-point absolute benefit in mRS 0–1 is one of the strongest signals we've seen in late-window stroke trials.

EXPECTS carved out a unique niche: posterior circulation strokes treated with alteplase out to 24 hours, selected by PC-ASPECTS. The 17-percentage-point benefit in functional independence (mRS 0–2: 89.6% vs 72.6%) was remarkable, with a minimal sICH signal (1.7% vs 0.9%). It proved that extended-window thrombolysis is not limited to the anterior circulation.

OPTION is the trial that answered the question no one else was asking: what about patients without large vessel occlusion? These are the M2 branch occlusions, the distal MCAs, the pure small vessel syndromes that don't qualify for thrombectomy but still cause real disability. OPTION showed that imaging-guided tenecteplase works here too — with a 9.4-percentage-point absolute benefit in excellent outcome (mRS 0–1: 43.6% vs 34.2%) and a safety profile that, while showing more sICH than placebo (2.8% vs 0%), was manageable in context.

The Synthesis

When you step back and look at the full body of evidence, three patterns emerge.

First: safety is a solved problem when selection is right. Across LVO, non-LVO, posterior circulation, and wake-up cohorts, symptomatic ICH in the 4.5–24 hour window stays in the 2–4% range. That's comparable to — sometimes better than — routine practice in the 0–4.5 hour window, where patient selection is often less rigorous and imaging less sophisticated.

Second: functional benefit is most consistent in non-LVO and selected LVO populations. The imaging has to match the biology. If there's no penumbra, lysis won't help. If the core is already massive, lysis might harm. But when the mismatch is real and the core is small, the benefit is consistent — regardless of whether it's hour six or hour twenty.

Third: tenecteplase has become the agent of choice. It's not just the convenience of a single bolus (though that matters). It's the fibrin specificity, the potentially better recanalization rates in LVO, and the cleaner safety signal in trial after trial. Alteplase still works — EXPECTS proved that in the posterior circulation — but TNK is emerging as the new standard.

What Major Centers Are Doing

Guidelines lag behind practice, and practice lags behind evidence. But the early adopters are already moving.

Several U.S. comprehensive stroke centers have implemented CTP-guided extended-window protocols as standard of care. If you show up at these hospitals at hour 12 with a disabling deficit and favorable imaging, you're getting lysis — full stop.

In Europe, adoption is more variable. Some centers are waiting for ECASS-4 or a formal guideline update. Others point to the neutral TIMELESS result and remain cautious. The European Stroke Organisation has issued conditional recommendations, but they're hedged with caveats about imaging expertise and patient selection.

Chinese centers, buoyed by the strength of TRACE-III in their population, have been the most aggressive. Extended-window thrombolysis is now routine practice at many large academic hospitals across China.

The 2026 AHA/ASA guidelines (Prabhakaran et al.) address extended-window IVT with imaging-based selection. That's a significant step — and the evidence base continues to grow as more trials read out.

The Open Questions

We've answered the big question — can we safely lyse patients beyond 4.5 hours — but several smaller questions remain.

Is plain alteplase still appropriate in the extended window, or has tenecteplase earned exclusivity? EXPECTS showed alteplase works in posterior circulation strokes. But TNK is easier, and probably better in the anterior circulation. If both are available, is there any reason to choose alteplase outside of the posterior fossa? The case is getting harder to make.

For LVO with mismatch, if late lysis recanalized the vessel, do we still need thrombectomy? This is the nightmare scenario for workflow — you give TNK at hour 8, the patient starts to improve, but the thrombectomy team is already prepping the suite. Do you abort? Do you proceed anyway? We don't have trial data to guide this decision, and it happens more often than you'd think.

What about patients without CTP capability? Not every hospital has perfusion imaging, and not every patient can tolerate the contrast load. Does a normal NCCT plus a favorable ASPECTS score allow extended IVT, or is perfusion imaging non-negotiable? EXPECTS used PC-ASPECTS rather than perfusion — suggesting simpler imaging selection can work in the right population. But for the anterior circulation, some centers are treating on ASPECTS alone while others consider that reckless. The evidence doesn't cleanly answer this yet.

Cost-effectiveness in non-LVO populations. OPTION was positive, but the absolute benefit was modest. In health systems with limited resources, is extended-window lysis for non-LVO strokes worth the imaging costs, the pharmacy costs, and the ICU monitoring? That's not a clinical question — it's an economic one, and it's going to shape access in ways that trials can't.

Bringing It Back to the Bedside

Let's go back to that 67-year-old woman who woke up with right-sided weakness. Her symptom onset time is unknown — maybe 8 hours, maybe 10. In the old paradigm, the conversation would have ended there. "I'm sorry, but you're outside the window. We can't give you the clot-busting drug."

In the new paradigm, the conversation starts there. You get a CTP. The images show a small core in the left MCA territory — maybe 15 mL — and a large penumbra. Mismatch ratio is 8:1. There's brain worth saving. You give tenecteplase. She goes to the ICU. Twelve hours later, her aphasia is gone and her arm is moving.

That outcome was impossible in 2015. It was experimental in 2020. In 2026, it's becoming standard of care.

"Time is brain — but tissue is the truth."

The 4.5-hour window was a workable approximation in an era when imaging was slow and our understanding of penumbra was crude. It was never a biological cliff. Ischemic brain doesn't suddenly become unsalvageable at 4 hours and 31 minutes. Penumbra can survive for 24 hours or more in the right patient, and we finally have the tools to identify those patients reliably.

The new standard treats the imaging — not the wristwatch — as the decision rule. For any patient presenting between 4.5 and 24 hours with a disabling deficit, the question is no longer "are they too late?" It's "do they have salvageable tissue?"

And if the answer is yes, we treat. Not because the guidelines told us to. Not because a trial gave us permission. But because the brain in front of us — the one lighting up on CTP, the one with penumbra still hanging on — deserves the chance.

That's the quiet revolution. And it changes everything.